Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Indresh Srivastava, Ph.D.

Vice President, Process & Analytical Development, Senior Program Manager - Influenza at Protein Sciences Corporation

Profile

Dr. Srivastava is trained as a biochemist and vaccinologist; has a broad background in biochemistry, biophysics, and immunology. He has been involved in the development of vaccines against malaria, HIV, SARS, HepC, Men B, West Nile and Flu in both academic and industrial environment for the last 25 years. More specifically designing, and developing novel immunogens using either the empirical or structure based rationale design; protein expression in different expression systems; and purification at small and large scales both in GLP and GMP environment. Dr. Srivastava has extensive experience in biophysical, biochemical and immunological characterization of vaccines, performing formulation development, and in taking new products to the Phase I/II clinical trials such as for HIV, CHIKV, and rHA. Dr. Srivastava’ broad experience is evident through his publications, and also the positions he held at Novartis Vaccines, NIAID, and currently at Protein Sciences. Dr. Srivastava is recognized as an expert in the field of immunogen design, purification and characterization, and has been routinely invited to participate in the NIH study sections to review investigator initiated grants (R01, R21 etc..) and program projects (HIVRAD, IPCAVD) for the last ten years. Based on his outstanding contributions, he has been appointed as the standing member of the Vaccine Study Section (VACC) for a four year term starting in 2015. He was a member of the advisory board for recommending the focus areas for the HIV research funding for Division of AIDS, and has been named in top 100 most powerful drug makers in the world, has been part of several scientific advisory boards. He has successfully managed dozens of collaborations, and projects more recently managing BARDA contracts awarded to PSC.

Indresh Srivastava, Ph.D.'s Network

Agenda Sessions